

OPEN DOOR POLICY FOR REPORTING COMPLAINTS REGARDING ACCOUNTING, AUDITING, FRAUD AND FINANCIAL MATTERS ("WHISTLEBLOWER POLICY")

Effective July 17, 2023

STATEMENT OF POLICY

Vitro Biopharma, Inc. and its subsidiaries (collectively, the "Company") is committed to providing a workplace conducive to open discussion of our business practices and is committed to complying with the laws and regulations to which we are subject. Accordingly, the Company will not tolerate conduct that is in violation of such laws and regulations. Each Company employee is encouraged to promptly report good faith complaints or concerns regarding accounting, auditing, internal accounting controls, fraud or violations of law, regulation or policy that could impact the Company's financial statements ("Compliance Matters") in accordance with the provisions of this whistleblower policy (this "Policy"). Employees who file reports or provide information without a good faith, reasonable belief in the truth and accuracy of such information are not protected by this Policy and may be subject to disciplinary action. Any other third party, such as vendors, collaborators, partners, stockholders or competitors, also may report, under the procedures provided in this Policy, a good faith complaint regarding Compliance Matters. To facilitate the reporting of complaints regarding Compliance Matters, the audit committee of our Board of Directors (the "Audit Committee") has established procedures for the receipt, retention and treatment of complaints regarding Compliance Matters.

This Policy is a supplement to the Company's Code of Conduct and Ethics (the "*Code*") and should be read in conjunction with the Code. After carefully reviewing this Policy, you must sign the acknowledgment attached as <u>Exhibit A</u> hereto, indicating that you have received, read, understand and agree to comply with this Policy. The acknowledgment must be returned either electronically in a manner provided for by the Company or to the Chief Financial Officer within ten (10) business days of your receipt of the Policy and as the Company may require.

SCOPE OF COMPLIANCE MATTERS COVERED BY THIS POLICY

This Policy covers complaints relating to Compliance Matters, including, without limitation, the following types of conduct:

• fraud, deliberate error or gross negligence or recklessness in the preparation, evaluation, review or audit of any financial statement or other disclosure of the Company;

- fraud, deliberate error or gross negligence or recklessness in the recording and maintaining of financial records or other disclosures of the Company;
- deficiencies in, or noncompliance with, the Company's internal accounting controls;
- misrepresentation or false statement to management, regulators, the outside auditors or others or by a senior officer, accountant or other employee regarding a matter contained in the financial records, financial reports or audit reports or with respect to other disclosures of the Company;
- deviation from full and fair reporting of the Company's results or financial condition;
- other violations of law, regulation or Company policy; or
- such other matters as may be referred by the Audit Committee to the Chief Financial Officer.

POLICY OF NON-RETALIATION

It is the Company's policy to comply with all applicable laws that protect our employees against unlawful discrimination or retaliation by us or our agents as a result of their lawfully reporting information regarding, or their participation in, investigations involving Compliance Matters. If any employee believes he or she has been subjected to any harassment, threat, demotion, discharge, discrimination or retaliation by the Company or its agents for reporting complaints regarding Compliance Matters in accordance with this Policy, he or she may file a complaint with the Compliance Officer, chairperson of the Audit Committee or the Company's human resources department. If it is determined that an employee has experienced any improper employment action in violation of this Policy, we endeavor to promptly take appropriate corrective action.

REPORTING OF COMPLAINTS

The Chief Financial Officer is responsible for receiving, reviewing and investigating complaints under this Policy (under the direction and oversight of the Audit Committee), and may be reached at nathan@vitrobiopharma.com. If an employee has a complaint regarding a Compliance Matter, he or she should report such matter to the Chief Financial Officer. If the suspected violation involves the Chief Financial Officer, the employee should instead report the suspected violation to the chairperson of the Audit Committee.

POLICY FOR RECEIVING AND INVESTIGATING COMPLAINTS

Upon receipt of a complaint, the Chief Financial Officer, who may consult with internal or external counsel, will determine whether the information alleged in the complaint pertains to a Compliance Matter. The Audit Committee shall be notified promptly of all complaints determined to pertain to a Compliance Matter and shall determine the planned course of action with respect to the complaint, including determining that an adequate basis exists for commencing an investigation. The Compliance Officer will then appoint one or more internal and/or external investigators to

promptly and fully investigate each viable claim under the direction and oversight of the Audit Committee or such other persons as the Audit Committee determines to be appropriate under the circumstances. The Chief Financial Officer, or the chairperson of the Audit Committee, will confidentially inform the reporting person that the complaint has been received and provide him or her with the name of, and contact information for, the investigator assigned to the claim.

Confidentiality of the employee submitting the complaint will be maintained to the fullest extent possible, consistent with the need to conduct an adequate investigation. In the course of any investigation, the Company may find it necessary to share information with others on a "need to know" basis. If the investigation confirms that a violation has occurred, the Company will promptly take appropriate corrective action with respect to the persons involved, including discipline up to and including termination, and, in appropriate circumstances, referral to governmental authorities, and will also take appropriate steps to correct and remedy any violation.

RETENTION OF COMPLAINTS

The Chief Financial Officer will maintain a log of all complaints, tracking their receipt, investigation and resolution, and shall prepare a periodic summary report thereof for each member of the Audit Committee. Each member of the Audit Committee and, at the discretion of the Chief Financial Officer, other personnel involved in the investigation of complaints, shall have access to the log. Copies of the log and all documents obtained or created in connection with any investigation will be maintained in accordance with our document retention policy.

Exhibit A

VITRO BIOPHARMA, INC.

OPEN DOOR POLICY FOR REPORTING COMPLAINTS REGARDING ACCOUNTING, AUDITING, FRAUD AND FINANCIAL MATTERS ("WHISTLEBLOWER POLICY") ACKNOWLEDGMENT

I hereby acknowledge that I have received, read, understand and will comply with Vitro Biopharma, Inc.'s Open Door Policy for Reporting Complaints Regarding Accounting, Auditing, Fraud and Financial Matters (the "Policy"). I will seek guidance from and raise concerns about possible violations of this Policy with my supervisor, management and the Chief Financial Officer or the chairperson of the Audit Committee, as appropriate. I understand that my agreement to comply with this Policy does not constitute a contract of employment.

Please sign here:	
Print Name:	-
Date:	
This signed and completed form must be return business days of receiving this Policy.	ed to the Chief Financial Officer within ten (10)